Literature DB >> 19457284

Reducing the cost of headache medication.

Glen D Solomon1.   

Abstract

Although medication costs make up one of the smallest portions of the overall expense of headache care, it is the segment of expense that often impacts the patient most directly. The advent of triptans marked a major advance in migraine therapy, but their high cost has limited their widespread use. Four options can be considered as potential means to reduce the cost of triptans. These include compulsory licensing, exclusive contracting, over-the-counter -availability, and the introduction of generic triptans. Each method impacts the consumer, third-party payer, or pharmaceutical company in a different manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457284     DOI: 10.1007/s11916-009-0038-5

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  3 in total

1.  Closing the affordability gap for drugs in low-income countries.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

2.  The ongoing regulation of generic drugs.

Authors:  Richard G Frank
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

Review 3.  Over-the-counter triptans for migraine : what are the implications?

Authors:  Peer Tfelt-Hansen; Timothy J Steiner
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

  3 in total
  2 in total

Review 1.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

2.  Low omega-6 vs. low omega-6 plus high omega-3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial.

Authors:  Christopher E Ramsden; J Douglas Mann; Keturah R Faurot; Chanee Lynch; Syed Taha Imam; Beth A MacIntosh; Joseph R Hibbeln; James Loewke; Sunyata Smith; Rebecca Coble; Chirayath Suchindran; Susan A Gaylord
Journal:  Trials       Date:  2011-04-15       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.